INSERM, UMR 599, Marseille
HIV-1 R5 variants preferentially infect CD62L- CD4+ cells and are potentially NRTI-resistant
Published in Health Insurance Week, April 9th, 2006
"The persistence of human immunodeficiency virus type I (HIV-1) in memory CD4+ T cells is a major obstacle to the eradication of the virus with current antiretroviral therapy.
"Here, we investigated the effect of the activation status of CD4+ T cells on the predominance of R5 and X4 HIV-1 variants in different subsets of CD4+ T cells in ex vivo-infected human lymphoid tissues and peripheral blood mononuclear cells (PBMCs)," scientists in France report.
According to F. Gondoisrey and colleagues...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Week
More Articles from Health Insurance Week
- Finance
Blue Cross Blue Shield of Michigan reports lower consolidated earnings - Finance
Wellpoint gives $15 million to California community colleges for nursing education - Healthcare Coverage
Over 80,000 uninsured Arkansans to get benefits under new U.S. HHS approved plan - Acologix
Acologix strengthens management team with addition of CFO - Alizyme plc
Alizyme reports positive preliminary results of phase IIa trial of ATL-104 for mucositis - Amarin Corp. plc
Amarin reports Miraxion improves stress hormone transport - More from this issue of Health Insurance Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
